Effects of Drospirenone 2 mg with 17-beta-Estradiol 1 mg on blood pressure and body weight in postmenopausal Korean women.
- Author:
Mi Young SHIN
1
;
Chan Woo WEE
;
Jung Kyung JOO
;
Ji Hyun KANG
;
In Sook JU
;
Kyoung Young SEO
Author Information
1. Department of Obstetrics and Gynecology, Seoul Veterans Hospital, Seoul, Korea. kvhsky@naver.com
- Publication Type:Original Article
- Keywords:
Hormonal treatment;
Blood pressure;
Body weight;
Drospirenone;
Postmenopause
- MeSH:
Androstenes;
Blood Pressure;
Body Weight;
Body Weight Changes;
Female;
Humans;
Postmenopause
- From:Korean Journal of Obstetrics and Gynecology
2009;52(10):1014-1021
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate effects of Drospirenone 2 mg (DRSP) with 17-beta-Estradiol 1 mg (E2) on blood pressure (BP) and body weight in postmenopausal Korean women. METHODS: BP and body weight were measured at baseline and 3 months of the treatment. We compared the change in BP and body weight between normotensive (group 1, control) and high-normotensive (group 2) group during treatment. And we compared the change in BP and body weight between hypertensive group receiving anti-hypertensive with (group 3) and without (group 4, control) DRSP/E2 during treatment. RESULTS: The mean systolic BP/diastolic BP of group 1 was not significantly decreased from baseline (116.9/75.0 mmHg) after treatment with DRSP/E2 for 3 months (116.1/73.2 mmHg) (P<0.152/P=0.088), however that of group 2 was significantly decreased from baseline (128.8/81.8 mmHg) after treatment with DRSP/E2 for 3 months (126.2/79.3 mmHg) (P<0.001/P=0.002). The mean systolic BP/diastolic BP of group 3 was significantly decreased from baseline (133.5/82.5 mmHg) after treatment with DRSP/E2 for 3 months (129.3/77.9 mmHg) (P<0.001/P<0.001), and that of group 4 was also significantly decreased from baseline (133.2/80.7 mmHg) after treatment with DRSP/E2 for 3 months (131.0/78.3 mmHg) (P=0.002/P<0.001). However change in the mean systolic BP/diastolic BP of group 3 was greater than that of group 4 (P=0.041/P=0.024). There was no weight change in all four groups. CONCLUSION: The use of DRSP/E2 showed a tendency to decrease the BP of high-normotensive or above in postmenopausal Korean women, and hypertensive patients receiving anti-hypertensive showed greater decline in BP. However there was no statistical significance in body weight change.
